New drug xiflam aims to ease long COVID symptoms in small trial

NCT ID NCT06437223

Completed Symptom relief Sponsor: Inflammx Therapeutics Inc Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This completed Phase 2 study tested whether the oral drug Xiflam (tonabersat) can safely reduce symptoms of Long COVID compared to a placebo. Sixteen adults who had COVID-19 and then developed lasting symptoms for at least 12 weeks took part. Participants received either Xiflam or a placebo daily for 12 weeks, and researchers tracked changes in symptoms like fatigue, brain fog, and eye issues using patient-reported scales.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Tonabersat (Xiflam)
What this could lead to: If successful, this could point toward a treatment to reduce the wide range of Long COVID symptoms, improving daily life for patients.
What could go wrong: This is a very small, early-phase trial with only 16 participants, so results may not apply to everyone. The drug may prove no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LONG COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

long COVID-19

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LONG COVID

Contacts and locations

Locations

Massachusetts Eye Research and Surgery Institution (MERSI)

Waltham, Massachusetts, 02451, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.